Limits...
Gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphoma.

Qian Z, Song Z, Zhang H, Wang X, Zhao J, Wang H - Biomed Res Int (2015)

Bottom Line: The GND regimen was well tolerated.A longer median OS was observed for group 1.Our study indicated that gemcitabine (800 mg/m(2)) on days 1 and 8 every 21 days was favorable for pretreated TCL patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tiyuanbei, Huanhuxi Road, Hexi District, Tianjin 300060, China.

ABSTRACT
T-cell lymphoma (TCL) is resistant to conventional chemotherapy. We retrospectively evaluated the therapeutic efficiency and toxicity of gemcitabine, navelbine, and doxorubicin (GND) in patients with refractory or relapsed TCL. From 2002 to 2012, 69 patients with refractory or relapsed TCL received GND treatment in our hospital. The treatment protocol comprised gemcitabine (800 mg/m(2), group 1; 1000 mg/m(2), group 2) on days 1 and 8, navelbine (25 mg/m(2)) on day 1, and doxorubicin (20 mg/m(2)) on day 1, repeated every 3 weeks. The overall response rate (ORR) was 65.2%. The median overall survival (OS) was 36 months. The 5-year estimated OS rate was 32.4%. The GND regimen was well tolerated. Subgroup analysis demonstrated that the ORR and CR for group 1 were similar. A longer median OS was observed for group 1. Significant difference in grades 3-4 toxicities was observed between groups 1 and 2 (P = 0.035). Our study indicated that gemcitabine (800 mg/m(2)) on days 1 and 8 every 21 days was favorable for pretreated TCL patients.

Show MeSH

Related in: MedlinePlus

The Kaplan-Meier estimate of overall survival (OS) for all patients.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4383323&req=5

fig1: The Kaplan-Meier estimate of overall survival (OS) for all patients.

Mentions: At the cut-off date of the follow-up examination (30 June 2013), the median follow-up time was 3.5 years for all patients and 4 years for surviving patients (range, 0.5–11 years). The median OS was 36 months (range, 5–67 months; 95% CI: 25.314–46.686) among all patients. The median OS was higher for patients from group 1 compared to patients from group 2 (37 versus 23 months, resp.). According to the Kaplan-Meier analysis, the 1-, 3-, and 5-year estimated OS rates for the whole cohort were 71.7%, 47.3%, and 32.4%, respectively (Figure 1). Estimators for 1-year OS rates were similar between groups 1 and 2 (72.2% versus 70.3%, resp.). However, we observed significant differences for the 3- and 5-year OS rates between patients from groups 1 and 2 (53.1% versus 30.1% and 36.5% versus 20.1%, resp. (Figure 2)).


Gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphoma.

Qian Z, Song Z, Zhang H, Wang X, Zhao J, Wang H - Biomed Res Int (2015)

The Kaplan-Meier estimate of overall survival (OS) for all patients.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4383323&req=5

fig1: The Kaplan-Meier estimate of overall survival (OS) for all patients.
Mentions: At the cut-off date of the follow-up examination (30 June 2013), the median follow-up time was 3.5 years for all patients and 4 years for surviving patients (range, 0.5–11 years). The median OS was 36 months (range, 5–67 months; 95% CI: 25.314–46.686) among all patients. The median OS was higher for patients from group 1 compared to patients from group 2 (37 versus 23 months, resp.). According to the Kaplan-Meier analysis, the 1-, 3-, and 5-year estimated OS rates for the whole cohort were 71.7%, 47.3%, and 32.4%, respectively (Figure 1). Estimators for 1-year OS rates were similar between groups 1 and 2 (72.2% versus 70.3%, resp.). However, we observed significant differences for the 3- and 5-year OS rates between patients from groups 1 and 2 (53.1% versus 30.1% and 36.5% versus 20.1%, resp. (Figure 2)).

Bottom Line: The GND regimen was well tolerated.A longer median OS was observed for group 1.Our study indicated that gemcitabine (800 mg/m(2)) on days 1 and 8 every 21 days was favorable for pretreated TCL patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tiyuanbei, Huanhuxi Road, Hexi District, Tianjin 300060, China.

ABSTRACT
T-cell lymphoma (TCL) is resistant to conventional chemotherapy. We retrospectively evaluated the therapeutic efficiency and toxicity of gemcitabine, navelbine, and doxorubicin (GND) in patients with refractory or relapsed TCL. From 2002 to 2012, 69 patients with refractory or relapsed TCL received GND treatment in our hospital. The treatment protocol comprised gemcitabine (800 mg/m(2), group 1; 1000 mg/m(2), group 2) on days 1 and 8, navelbine (25 mg/m(2)) on day 1, and doxorubicin (20 mg/m(2)) on day 1, repeated every 3 weeks. The overall response rate (ORR) was 65.2%. The median overall survival (OS) was 36 months. The 5-year estimated OS rate was 32.4%. The GND regimen was well tolerated. Subgroup analysis demonstrated that the ORR and CR for group 1 were similar. A longer median OS was observed for group 1. Significant difference in grades 3-4 toxicities was observed between groups 1 and 2 (P = 0.035). Our study indicated that gemcitabine (800 mg/m(2)) on days 1 and 8 every 21 days was favorable for pretreated TCL patients.

Show MeSH
Related in: MedlinePlus